[Impact of short-term neoadjuvant hormonal treatment on neuroendocrine differentiation in prostate carcinoma]

Zhonghua Zhong Liu Za Zhi. 2003 Sep;25(5):493-5.
[Article in Chinese]

Abstract

Objective: To study the impact of short-term neoadjuvant hormonal treatment on neuroendocrine (NE) differentiation and the relation of NE differentiation and tumor regression.

Methods: The radical prostatectomy specimens and the biopsy specimens of the same 18 patients with prostate cancer were compared. The effect of hormonal treatment on NE-differentiation was evaluated by specific antibodies against chromogranin A (ChA) and serotonin (5-HT).

Results: The ChA-positive cell count was 3.2 x 10(-5)/microm(2) [(0-5.7) x 10(-5)/microm(2)] before hormonal treatment and 2.3 x 10(-5) microm(2)[(0-6.6) x 10(-5)/microm(2)] afterward (P > 0.05). For the proportion of NE-positive tumor, it was 7.0% (0%-14.9%) and 4.5% (0%-13.1%) (P > 0.05). No correlation existed between NE-differentiation and the neoadjuvant hormonal treatment. The NE cell density did not differ significantly between 12 non-/slightly regressive tumor foci and 6 highly regressive ones (P > 0.05).

Conclusion: Short-term neoadjuvant hormonal therapy does not induce clonal propagation of NE cells. The degree of tumor regression following short-term neoadjuvant hormonal therapy is not correlated with the NE differentiation.

Publication types

  • English Abstract

MeSH terms

  • Aged
  • Androgen Antagonists / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Chromogranin A
  • Chromogranins / analysis
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neurosecretory Systems / pathology*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology*
  • Serotonin / analysis

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Chromogranin A
  • Chromogranins
  • Serotonin